ORGANIZATION

• National Univ. Hospital Council to Disclose Funding with Companies’ Names Not Affiliated with JPMA
  April 27, 2016

• JPMA Official Calls for Use of Academic Data in Drug Submissions
  April 26, 2016

• Quakes Injure 3, Cause Property Damage for 22 Companies: JPMA Survey
  April 20, 2016

• JPMA Sets Up Taskforce for Russia, Brazil, Mexico, Turkey
  April 18, 2016

• Contract Sales Reps in Japan Likely to Increase to 6,000 in 2021: Industry Group
  April 15, 2016

• Japan at a Crossroads as Investment Destination, World’s Eyes Riveted on Govt’s Signals: PhRMA Local Chief
  April 13, 2016

• EFPIA Japan Chief to Call for “Real Dialogue” at Today’s Public-Private Policy Confab
  April 12, 2016

• Asian Industry Groups Agree to Continue Efforts to Improve Access to Innovative Medicines in Asia
  April 11, 2016

• Front-Loaded Price Cuts Necessary for Drugs Like Opdivo: JMA’s Nakagawa
  April 7, 2016

• Japan Pharma Groups Step Up Lobbing Campaigns to Skirt Further Drug Cost Cuts
  April 7, 2016

• Generic Use Rate at 56.1% in October-December 2015: JGA
  April 1, 2016

• JPMA Issues Notification Urging Member Companies to Strengthen Internal Ad Review Systems
  March 25, 2016

• FPMAJ Braced for Thorny Path Ahead Even If Sales Tax Postponed, Revenue Falls Would Weigh on Industry: Chief
  March 18, 2016

• Discuss Role of Drugs in Overall Social Security System: Full Interview with FPMAJ Pricing Affairs Chief
  March 18, 2016

• “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
  March 10, 2016

• PhRMA Japan Committee Sets Out Guiding Principles for MSLs
  February 26, 2016

• FY2016 Reimbursement Policy Reform “Tough” on Industry: JPMA
  February 19, 2016

• Top MHLW Bureaucrat Says 80% Generic Share “Achievable”
  February 16, 2016

• Former JMA Pres. Eitaka Tsuboi Dies at 86
  February 15, 2016

• EFPIA Japan Lays Out Basic Principles on MSL Activities
  February 4, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• 57
• …
• Next ›
• 最終 »